
The increasing efficacy of pediatric cancer therapy over the past four decades has produced many long-term survivors that now struggle with serious treatment related zzso affecting their quality of zzso zzso therapy is responsible for a significant proportion of these late effects, but a relatively new and emerging zzso zzso zzso hold great promise to drastically reduce these treatment related late effects in long term survivors by sparing dose to normal zzso zzso studies of zzso zzso compared with best available zzso based treatment show significant dose sparing to developing normal zzso Furthermore, clinical data are now emerging that begin to zzso the benefit in decreased late treatment effects while maintaining excellent cancer control zzso 

